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Because there is little routine tuberculosis (TB) screen-
ing in Mexico, the prevalence of latent TB infection (LTBI) 
is unknown. In the context of an increasing HIV epidemic in 
Tijuana, Mexico, understanding prevalence of LTBI to an-
ticipate emergence of increased LTBI reactivation is critical. 
Therefore, we recruited injection drug users, noninjection 
drug users, female sex workers, and homeless persons for 
a study involving risk assessment, rapid HIV testing, and TB 
screening. Of 503 participants, the overall prevalences of TB 
infection, HIV infection, and TB/HIV co-infection were 57%, 
4.2%, and 2.2%, respectively; no signiﬁ  cant differences by 
risk group (p>0.05) were observed. Two participants had TB 
(prevalence 398/100,000). Incarceration in Mexico (odds 
ratio [OR] 2.28), age (OR 1.03 per year), and years lived in 
Tijuana (OR 1.02 per year) were independently associated 
with TB infection (p<0.05). Frequent LTBI in marginalized 
persons may lead to increases in TB as HIV spreads.
T
uberculosis (TB) is endemic to Mexico. The national 
TB incidence is estimated to be 16.2 cases/100,000, 
but regional rates, particularly along the United States–
Mexico border are much higher (1). Baja California, which 
shares a border with California, has the highest incidence 
of pulmonary TB in Mexico (57 cases/100,000), which 
is >3× the national average (2). Furthermore, California 
and Baja California have the highest incidence rates of all 
the border states in their respective countries (1). Trans-
mission of TB from high-prevalence countries to low-
prevalence countries, such as the United States, poses a 
major public health concern. Tijuana, the largest city in 
Baja California, Mexico, lies ≈20 miles south of down-
town San Diego, California, and these 2 cities are loosely 
separated by the busiest land border crossing in the world, 
with >90,000 passenger vehicles crossing in both direc-
tions daily (3). As a possible consequence of this close 
binational association, San Diego has a slightly higher 
incidence of TB than California (8.4 per 100,000 and 7.0 
per 100,000, respectively) (4,5).
Otherwise healthy persons with dormant or latent tu-
berculosis infection (LTBI) have a 10% lifetime risk that 
dormant mycobacteria will become active and cause TB. 
Persons co-infected with HIV and LTBI have a risk for 
TB reactivation of 10% per year (6). Consequently, TB 
is a leading cause of death worldwide among persons co-
infected with TB and HIV (7). Although HIV prevalence 
in Mexico is lower than that in the United States, Tijuana 
is currently experiencing an emerging HIV epidemic (8), 
with increasing prevalence observed among high-risk 
groups such as injection drug users (IDUs) and female sex 
workers (FSWs) (9–11). The potential for rapid HIV trans-
mission among IDUs in Mexico is highlighted by ﬁ  ndings 
from Tijuana and Ciudad Juarez (a border city south of El 
Paso, Texas), which showed that 95% of IDUs in these cit-
ies had antibodies against hepatitis C virus (a marker of un-
safe injection practices), and most IDUs had self-reported 
risk factors for sexual or parenteral exposure to HIV (12). 
Latent Tuberculosis among Persons 
at Risk for Infection with HIV, 
Tijuana, Mexico 
Richard S. Garfein, Rafael Laniado-Laborin, Timothy C. Rodwell, Remedios Lozada, Robert Deiss, 
Jose Luis Burgos, Jazmine Cuevas-Mota, Paris Cerecer, Kathleen Moser, Maria Luisa Volker, 
and Steffanie A. Strathdee
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 5, May 2010  757 
Author afﬁ   liations: University of California San Diego School of 
Medicine, San Diego, California, USA (R.S. Garfein, T.C. Rodwell, 
R. Deiss, J.L. Burgos, J. Cuevas-Mota, S.A. Strathdee); Univer-
sidad Autonoma de Baja California, Tijuana, Mexico (R. Laniado-
Laborin); Patronato Pro-Comité Municipal de Prevención del SIDA, 
Tijuana (R. Lozada); Instituto de Servicios de Salud Pública del 
Estado de Baja California, Tijuana (P. Cerecer, M.L. Volker); and 
San Diego County Department of Health and Human Services, San 
Diego (K. Moser)
DOI: 10.3201/eid1605.091446RESEARCH
Thus, there is concern that increased HIV incidence would 
result in LTBI reactivation among IDUs who spread active 
TB to other populations, which would lead to a more gen-
eralized epidemic.
Homeless persons and noninjecting drug users (NIDUs) 
are also at increased risk for co-infection with TB/HIV. In 
low-prevalence countries, these risk groups have higher 
rates of LTBI than those in the general population (13–15). 
Although estimates of LTBI and their correlates among 
FSWs are not well documented, an increasing percentage 
of FSWs in Tijuana are infected with HIV and report mul-
tiple potential risk factors for TB, including injection drug 
use and sexual contact with IDUs (10). Thus, the need for 
accurate estimates of LTBI prevalence in high-risk margin-
alized populations is clear.
In the United States, LTBI screening and prophylactic 
treatment have played a major role in reducing co-infection 
with TB/HIV in most regions and communities. However, 
LTBI screening, which is usually conducted by using the 
tuberculin skin test (TST), is uncommon in countries such 
as Mexico, which still uses Mycobacterium bovis BCG vac-
cination universally, because the TST has reduced speciﬁ  c-
ity in vaccinated persons (16). Whole-blood interferon-γ 
release assays (IGRAs), which measure cellular immune 
response to puriﬁ  ed proteins found in M. tuberculosis, but 
not in BCG vaccine strains, provide a means for more accu-
rately estimating TB infection prevalence in countries such 
as Mexico (17). A study that measured TB infection preva-
lence in Mexico by using an IGRA found that 67% of IDUs 
in Tijuana were positive (18). However, that study did not 
differentiate between LTBI and active TB and included 
only IDUs. The purposes of the current study, known as 
PreveTB, were to measure the prevalence of TB and HIV 
among marginalized populations of Tijuana who are at a 
high risk for becoming co-infected with HIV and TB, esti-




Participants were recruited in Tijuana, Mexico, during 
April 2007–July 2007, by street outreach, targeted adver-
tising, and word-of-mouth. Persons were eligible to par-
ticipate if they were >18 years of age, provided informed 
consent, planned on staying in Tijuana for the next 30 days, 
and reported at least 1 of the following characteristics in the 
6 months before enrollment: use of noninjected illicit drugs 
other than marijuana, injection drug use, receipt of money/
goods in exchange for sex, and homelessness or unstable 
housing. Unstable housing was deﬁ  ned as living primarily 
in a rented hotel room, migrant work camp, or medical/
drug treatment facility.
Data Collection
Participant interviews were conducted and biologi-
cal samples were obtained at PrevenCasa, a community-
based harm-reduction and research facility located in the 
Zona Norte neighborhood of Tijuana, which abuts the 
commercial sex trade district. Computer-assisted personal 
interviewing technology (QDS; Nova Research Company, 
Bethesda, MD, USA) was used to facilitate participant in-
terviews. Interviews were conducted in Spanish by trained 
Mexican interviewers experienced with the speciﬁ  c popu-
lations. Questions included sociodemographic character-
istics, putative risk factors for TB and HIV infection, TB 
knowledge and exposure history, and presence of TB-re-
lated symptoms. The survey instrument was developed in 
English, translated into Spanish, and then back-translated 
into English to verify accuracy and meaning. Monetary re-
imbursement of US $20 was offered to participants to com-
pensate them for time and transportation.
During the computer-assisted personal interview, per-
sons who reported a persistent cough for >3 weeks and an 
additional symptom indicative of TB (fever or chills, night 
sweats, swollen lymph nodes, hoarseness, shortness of 
breath, joint pain, fatigue, and unexplained weight loss) or 
hemoptysis with or without other symptoms, were consid-
ered suspected active TB case-patients. After the interview, 
these persons were asked to provide 3 sputum samples for 
acid-fast bacilli (AFB) smears; the ﬁ  rst of these samples 
was collected immediately. The remaining 2 samples were 
collected on subsequent days. These participants were also 
transported to a nearby radiologic center for chest radi-
ography to identify evidence of pathologic changes con-
sistent with TB. Incentives of US $5 were given for each 
additional sputum collection visit and upon completion of 
a chest radiograph, as recommended by FitzGerald et al. 
(19). Participants with >1 AFB-positive sputum smear or 
chest radiography ﬁ  ndings consistent with TB were deter-
mined likely to have active TB and were referred to the 
central public health clinic (Instituto de Servicios de Salud 
Pública del Estado de Baja California [ISESALUD]) for 
clinical conﬁ  rmation and treatment through the national TB 
program. The study protocol was reviewed and approved 
by ethics committees at the University of California, San 
Diego, and the Tijuana General Hospital.
Laboratory Testing
M.  tuberculosis infection was detected by using an 
IGRA (QuantiFERON TB Gold In-Tube [QFT] assay; 
Cellestis Ltd., Carnegie, Victoria, Australia), an in vitro as-
say that uses an ELISA to detect interferon-γ released by 
whole blood samples after introduction of 6-kDa early se-
cretory antigenic target protein, culture ﬁ  ltrate protein 10, 
and TB7.7 protein, which mimic antigens speciﬁ  c to the 
M. tuberculosis complex present in patients with TB and 
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LTBI (20). In 2005, the US Food and Drug Administration 
(Silver Spring, MD, USA) approved the QFT assay for de-
tection of M. tuberculosis infection, and the US Centers for 
Disease Control and Prevention (Atlanta, GA, USA) deter-
mined that this assay may be used to detect M. tuberculosis 
in all situations in which the TST is used (17). Antibodies 
against HIV were detected by using the Determine Rapid 
HIV Antibody Test (Abbott Laboratories, Boston, MA, 
USA) on site. All positive test results were conﬁ  rmed at the 
San Diego County Public Health Laboratory by using an 
ELISA and an immunoﬂ  uorescent antibody assay.
After data collection, all persons who did not report 
symptoms consistent with active TB were given an appoint-
ment 4 weeks later to receive the results of the HIV test and 
QFT assay. At this visit, those who were HIV positive were 
referred to ISESALUD for medical evaluation, and those 
who were IGRA positive were offered chest radiography 
when they returned to obtain results that ruled out active 
TB. Persons who had active TB by AFB smear or radiogra-
phy were referred to ISESALUD. Persons who were IGRA 
positive, but had an unremarkable chest radiograph, were 
determined to have LTBI.
Statistical Analysis
Descriptive statistics were used to characterize par-
ticipants by IGRA status. Associations between participant 
characteristics and TB infection were evaluated by using 
the Wilcoxon rank-sum test or Fisher exact test, followed 
by univariate and multivariate logistic regressions. Vari-
ables with p values <0.10 in univariate models were con-
sidered for inclusion in multivariate analysis. A backward 
stepwise model that selected for main effects in the ﬁ  nal 
model was used. At each step, likelihood ratio testing was 
used to compare nested models until only variables with p 
values <0.05 remained in the ﬁ  nal model.
Results
Prevalence of HIV and TB Infection
A total of 527 persons were recruited, of whom 503 met 
eligibility criteria and had complete HIV and IGRA results. 
Overall, 57% were positive for TB infection by QFT assay 
(IGRA+), 4.2% were HIV+ by HIV test, and 2.2% were 
positive by both tests. Fifty-nine percent of participants 
were men, median age was 36 years (interquartile range 
29–42 years), and median length of time participants had 
lived in Tijuana was 6 years (interquartile range 1.0–13.3 
years). On the basis of nonmutually exclusive groupings, 
there were 232 (46%) IDUs, 311 (62%) NIDUs, 115 (23%) 
FSWs, and 280 (56%) homeless persons. The prevalence of 
IGRA+ results was 63% among IDUs, 58% among NIDUs, 
49% among FSWs, and 52% among homeless participants. 
A total of 14 (2.8%) participants reported symptoms sug-
gestive of active TB, of which 2 persons were diagnosed 
with active TB by AFB+ smears (prevalence 398/100,000). 
Because chest radiography was used after recruitment be-
gan and was offered at the results visit, only 79 of the 286 
IGRA+ participants had chest radiography, of which 8 
(10%) had signs of current or past pulmonary TB.
Correlates of TB Infection
Univariate analysis identiﬁ  ed several factors associ-
ated with TB infection (Table 1). When compared with 
IGRA– participants, IGRA+ participants were signiﬁ  cantly 
older (median age 38 vs. 34 years; p<0.01), had lived in Ti-
juana longer (median 9.0 vs. 3.5 years; p<0.01), were more 
likely to be men (64.7% vs. 51.6%; p<0.05), had stable 
sleeping arrangements in the 6 months before data collec-
tion (49.3% vs. 37.8%; p<0.05), and had known someone 
with TB (46.2% vs. 35.9%; p<0.05). When compared with 
those not in each risk group, IDUs were more likely to be 
IGRA+, and FSWs and homeless participants were less 
likely to be IGRA+; no association was found for NIDUs. 
History of incarceration was associated with TB infection. 
Persons who had been incarcerated in Mexico were more 
likely to be IGRA+ (68%) than those incarcerated in the 
United States (55%) or both countries (62%). To maximize 
statistical power, in subsequent analyses we combined 
incarceration in Mexico and the United States into 1 in-
carceration category. When compared with IGRA– par-
ticipants, IGRA+ participants were no more likely to report 
sexually transmitted infections (2.5% vs. 2.3%; p = 0.91) or 
be HIV+ (3.8% vs. 4.6%; p = 0.67). TB infection was not 
associated with any other drug administration practice or 
sexual behavior examined in this study.
Multivariate logistic regression analysis (Table 2) 
showed that TB infection was independently associated 
with age, increasing years of Tijuana residence, and a his-
tory of being incarcerated in Mexico or in Mexico and the 
United States. For each 1-year increase in age and time lived 
in Tijuana, participants were 1.03× (95% conﬁ  dence inter-
val [CI] 1.01×–1.05×) and 1.02× (95% CI 1.01×–1.04×) 
more likely to be IGRA+, respectively. Persons who had 
a history of being jailed in Mexico were 2.28× (95% CI 
1.48×–3.51×) more likely to be IGRA+ than those who had 
never been incarcerated.
Discussion
We found a high prevalence of TB infection among 
marginalized populations at high risk for HIV infection in 
Tijuana. Although HIV prevalence in this study (4.2%) was 
lower than estimates reported among similar populations 
elsewhere (21,22), it was higher than that of the general 
population of Baja California, Mexico (0.8%–0.9%) (9,23). 
If HIV prevalence increases among groups who have high 
LTBI prevalence, reactivation and spread of TB will ham-
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per TB control efforts in the region. Interventions are need-
ed that prevent HIV transmission and LTBI reactivation.
Among IDUs in this study, the TB infection prevalence 
(63%) was consistent with that in an earlier study of IDUs 
in Tijuana (18), which reported a crude prevalence of 67% 
and a prevalence of TB infection of 64% after the estimate 
was adjusted for respondent-driven sampling. This method 
of sampling of hidden populations enables researchers to 
adjust prevalence estimates to account for sampling bias 
(24). In addition to conﬁ  rming the high prevalence of LTBI 
among IDUs in Tijuana, we found a disturbingly high 
LTBI prevalence among other hard-to-reach groups. Given 
that the reference group for associations found between 
FSWs or homelessness and LTBI status was mostly IDUs, 
it was not surprising that these factors had odds ratios less 
than unity. Further studies that include low-risk groups are 
needed to determine the risk for LTBI among FSWs and 
homeless persons relative to the general population.
Unlike our earlier study (18), in which we referred per-
sons with TB symptoms directly to a community clinic for 
further evaluation, the current study included AFB smear 
microscopy and chest radiography to detect active TB be-
fore referring participants for care. These modiﬁ  cations 
enabled us to estimate the prevalence of active TB. Our 
estimate of TB disease prevalence (398/100,000) was ≈4× 
higher than the reported TB prevalence for Baja California. 
Although this estimate is based on a small number of cases, 
the fact that AFB smears can miss up to 40% of culture-
positive TB cases (25) indicates that this ﬁ  nding is likely 
a conservative estimate. Our ﬁ  ndings concur with those of 
other studies, which showed that substance abuse, injection 
drug use in particular, is associated with increased risk for 
active TB (26).
Age and years of residence in Tijuana were associ-
ated with increased odds of TB infection. This ﬁ  nding, 
along with the fact that TB incidence was estimated to be 
57/100,000 in Baja California versus the national rate of 
16.2/100,000, suggests that living in this region of Mexico 
may increase the risk for acquiring M. tuberculosis infec-
tion (1). Although having spent time in jail or prison was 
associated with TB infection in our study, having spent 
time in a correctional facility in Mexico appeared to be 
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Table 1. Univariate analysis of factors associated with tuberculosis infection status among high-risk groups for HIV in Tijuana, Mexico, 
April–July 2007* 
Characteristic  Total (n = 503)  IGRA– (n = 217)  IGRA+ (n = 286)  Odds ratio (95% CI) 
Risk factor†‡         
  Injected drugs  232 (46.1)  86 (39.6)  146 (51.1)  1.59 (1.11–2.27) 
  Used drugs but never injected  207 (41.2)  94 (43.3)  113 (39.5)  0.86 (0.60–1.22) 
  Sex work  115 (22.9)  59 (27.2)  56 (19.6)  0.65 (0.43-0.99) 
  Homeless/unstably housed  280 (55.7)  135 (62.2)  145 (50.7)  0.63 (0.44–0.90) 
  Median age, y (IQR)  36.0 (29–42)  34.0 (28–40)  38.0 (31–43)  1.04 (1.02–1.06) 
Sex        
  M  297 (59.0)  112 (51.6)  185 (64.7)  1.00 
  F  193 (38.4)  99 (45.6)  94 (32.9)  0.58 (0.40–0.83) 
  Transgender  13 (2.6)  6 (2.8)  7 (2.5)  0.71 (0.23–2.16) 
Years lived in Tijuana, median (IQR)  6.04 (1–13.3)  3.51 (0.3–10.0)  9.0 (3.0–16.4)  1.03 (1.012–1.04) 
Most frequent type of sleeping arrangement‡         
  Stable  223 (44.3)  82 (37.8)  141 (49.3)  1.00 
  Unstable housing  209 (41.6)  105 (48.4)  104 (36.4)  0.58 (0.39–0.85) 
  Homeless  71 (14.1)  30 (13.8)  41 (14.3)  0.80 (0.46–1.37) 
Ever incarcerated  338 (67.2)  128 (59.0)  210 (73.4)  1.92 (1.32–2.80) 
Incarceration status         
  Never jailed  165 (32.8)  89 (41.0)  76 (26.6)  1.00 
  Jailed in USA only  129 (25.6)  58 (26.7)  71(24.8)  1.43 (0.90–2.28) 
  Jailed in Mexico or Mexico and USA  209 (41.5)  70 (32.3)  139 (48.6)  2.33 (1.53–3.54) 
Noninjection drug used most often‡         
  None  157 (31.2)  67 (30.9)  90 (31.5)  1.00 
  Methamphetamines  218 (43.3)  101 (46.5)  117 (40.9)  0.86 (0.57–1.30) 
  Heroin  52 (10.3)  14 (6.5)  38 (13.3)  2.02 (1.01–4.03) 
  Any other drug  76 (15.1)  35 (16.1)  41 (14.3)  0.87 (0.50–1.51) 
Ever injected illegal drugs  248 (49.3)  92 (42.4)  156 (54.6)  1.63 (1.14–2.33) 
Mean (SD) years injected drugs among IDUs  13.5 (13.0)  13.0 (13.5)  14.0 (14.0)  1.02 (0.99–1.05) 
Ever known anyone with TB  210 (41.8)  78 (35.9)  132 (46.2)  1.53 (1.06–2.19) 
*Values are no. (%) unless otherwise indicated. IGRA, interferon-Ȗ release assay; CI, confidence interval; IQR, interquartile range; IDUs, injection drug 
users; TB, tuberculosis. 
†Risk groups are not mutually exclusive; reference group includes all participants without the characteristic. 
‡Refers to the past 6 mo.  TB and HIV, Tijuana, Mexico
a major risk factor, regardless of also having spent time 
in a correctional facility in the United States. Transmis-
sion of TB is facilitated by close contact with infectious 
persons, such as those found in correctional facilities, and 
increased TB incidence rates have been documented dur-
ing incarceration (27,28). Inmates at facilities in Mexico 
may have a higher risk for infection because of the higher 
prevalence of TB in Mexico than in the United States, 
the greater densities of inmates in these facilities, and the 
lack of LTBI screening programs in Mexico. These cor-
rectional facilities offer a unique opportunity to reduce 
TB in the community at large (29).
The World Health Organization has estimated that one 
third of the world’s population has LTBI (7), which creates 
a massive reservoir of disease that is considered a major 
threat to global TB control (30). Persons co-infected with 
TB and HIV are at greatest risk for reactivation of LTBI; 
they have an incidence of ≈35–162 cases/1,000 person-
years. The second and third highest risks for LTBI reac-
tivation occurs among persons who were recently infected 
(<12 months earlier) and IDUs, who collectively have an 
incidence of ≈10–12.9/1,000 person-years, which is inde-
pendent of their HIV status (31). However, in Mexico suf-
ﬁ  cient resources are not available to treat all with LTBI 
cases. Therefore, treatment is restricted to those with LTBI 
cases considered at high risk for reactivation, which is cur-
rently deﬁ  ned as children who have had contact with in-
fectious TB case-patients and those co-infected with HIV. 
As new diagnostic tools capable of identifying LTBI cases 
at imminent risk for progressing to TB are developed, TB 
control programs in places such as Tijuana could expand 
treatment of persons with LTBI in a focused, cost-efﬁ  cient 
manner (32).
The cross-sectional design of our study precluded us 
from drawing temporal inferences between TB infection 
and risk factors we examined. Moreover, information ob-
tained about recent behavior (substance and drug use, sex-
ual behavior, and housing status) may not reﬂ  ect patterns 
present at the time participants became infected. This ﬁ  nd-
ing could explain why our analysis identiﬁ  ed that only life-
time variables were independently associated with TB in-
fection. In addition, this study used convenience sampling 
methods to enroll participants. Therefore, our results may 
not be representative of other marginalized populations in 
Mexico. M. bovis infections, which accounted for <17% of 
TB infections in persons born in Mexico who were living in 
southern California from 2001 through 2005 (33), can also 
cause an IGRA+ result. Thus, some IGRA+ results in this 
study may have been caused by M. bovis infections rather 
than M. tuberculosis infections. However, we do not be-
lieve that this possibility changes our conclusions because 
TB caused by M. bovis and TB caused by M. tuberculosis 
are essentially indistinguishable clinically (34), and both 
infections cause illness and death in this region (33), which 
are exacerbated by HIV infection.
Our results were based on an IGRA, and although 
there is no standard procedure for detecting LTBI, studies 
have consistently reported that IGRAs are more sensitive 
and speciﬁ  c for detecting active TB than are TSTs (35). In 
addition, 78% of the study participants had a visible BCG 
scar, which suggested that LTBI would have been over-
estimated if based on a TST in this population. Although 
the LTBI estimates in this study suggest treatment speciﬁ  c 
for high-risk groups, additional studies are needed to obtain 
comparable estimates from the general population to deter-
mine whether interventions should be speciﬁ  c for certain 
groups or the general population.
Although prevention of infection with HIV should 
be the top priority for reducing TB risk, the high LTBI 
prevalence found in this study indicates an unmet need for 
early TB identiﬁ  cation and treatment among populations 
in Tijuana at risk for HIV infection. TB and HIV screen-
ing and treatment can be difﬁ  cult to accomplish, given that 
these hard-to-reach populations access medical care infre-
quently, and drug users and homeless populations have ad-
ditional barriers to compliance with TB treatment regimens 
(36,37). Ofﬁ  cial guidelines in Mexico currently recommend 
treatment for LTBI only for exposed children <5 years of 
age, children 5–14 years of age if they have no history or 
signs of BCG vaccination, and HIV-infected persons with 
known exposure to a person with an active case of TB (38). 
However, a separate economic analysis has shown that an 
LTBI screening program similar to that demonstrated in 
this study, together with an LTBI treatment strategy, would 
be cost-effective among IDUs in Tijuana (39). Additional 
studies are needed to determine whether treatment of LTBI 
would also be cost-effective for the general population and 
other groups at high risk for TB/HIV co-infection. Ex-
panded TB and HIV screening efforts, coupled with HIV 
risk reduction interventions and education about TB among 
these high-risk populations, are needed to avoid reactiva-
tion and spread of TB resulting from emergence of HIV in 
this Mexico/United States border region.
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Table 2. Multivariate analysis of factors associated with 
tuberculosis infection status among high-risk groups for HIV in 
Tijuana, Mexico, April–July 2007* 
Characteristic
Adjusted odds ratio 
(95% Cl) 
Age, y   1.03 (1.01–1.05) 
Years lived in Tijuana  1.02 (1.01–1.04) 
Incarceration status 
 Never  jailed  1.00
  Jailed in USA only  1.61 (0.98–2.63) 
  Jailed in Mexico or in Mexico and USA  2.28 (1.48–3.51) 
*Odds ratios were adjusted for all other variables. CI, confidence interval. RESEARCH
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